Baird Medical Investment Holdings Ltd Ordinary Share - BDMD STOCK NEWS

Baird Medical (NASDAQ: BDMD) showcased its microwave ablation technology at the Massachusetts Society of Otolaryngology (MSO) event, highlighting its benefits for minimally invasive, office-based surgical procedures. The technology promises higher precision, reduced procedure time, and improved patient recovery, aligning with current trends in Otolaryngology. Attendees showed strong interest in the technology's potential to enhance patient care outcomes and practice efficiency. Baird Medical reaffirmed its commitment to supporting the Otolaryngology community with advanced tools.

Baird Medical (BDMD) showcased its microwave ablation (MWA) technology at the 2024 American Thyroid Association Annual Meeting, drawing significant international attention. The event featured presentations by notable experts, including Dr. Emad Kandil from Tulane University and Dr. Feng Han from Sun Yat-sen University Cancer Center. Dr. Kandil presented clinical data demonstrating MWA's success in cases where RFA failed, emphasizing its safety and effectiveness for thyroid nodule treatment. Dr. Han shared insights on advanced procedural techniques and energy management based on his extensive experience with MWA procedures. The event concluded with hands-on demonstrations of Baird's technology.

Baird Medical hosted and participated in several key thyroid health events from October 24-27, 2024, fostering international collaboration between U.S. and Chinese experts. The company organized the Sixth Global Thyroid Microwave Ablation Technology Exchange Conference on October 25, focusing on advancements in microwave ablation for benign thyroid nodules. Additionally, Baird participated in the 9th Annual China Thyroid Association Conference, the inaugural Western Thyroid Diagnosis and Endoscopy Training Session, and the 4th Hunan Thyroid and Breast Health Forum, demonstrating its commitment to advancing global thyroid care standards.

Baird Medical (NASDAQ: BDMD) participated in the 2024 American College of Surgeons Clinical Congress in San Francisco, showcasing its microwave ablation (MWA) technology to over 10,000 attendees, including 7,000 surgeons. At Booth 1061, the company demonstrated MWA applications for thyroid nodules, breast disease, liver cancer, and uterine fibroids. The technology, already adopted by institutions like Columbia University and Weill Cornell, attracted significant interest through hands-on simulations. Baird participated in panel discussions on ablative therapies and engaged with endocrine surgery leaders, reinforcing its commitment to market expansion.

Baird Medical Investment Holdings (NASDAQ: BDMD), a leading developer of microwave ablation (MWA) medical devices, announced its participation in the American Thyroid Association (ATA) Annual Meeting from October 30 to November 3, 2024, in Chicago. The company will showcase its innovations at Booth 100 and host an Expo Theater Presentation on November 2, titled 'Latest Advancements in MWA for Thyroid Treatment'.

The presentation will feature experts from Tulane University, Sun Yat-sen University, and Houston Methodist Hospital. Baird Medical's participation highlights its expansion into the U.S. market following FDA clearance for its MWA technology, offering a minimally invasive alternative to thyroidectomy for benign thyroid tumors. With over 150,000 thyroidectomies performed annually in the U.S., Baird Medical's technology presents a safer option for patients.

Baird Medical Investment Holdings (NASDAQ: BDMD) announced preliminary financial results for the six months ended June 30, 2024. Total revenues increased by 13.8% year-over-year to US$13.1 million. Gross profit rose 20.9% to US$11.5 million, while operating income grew 70.0% to US$5.1 million. Net income saw a significant increase of 85.8% to US$4.4 million.

CEO Haimei Wu highlighted the company's strong performance in China and initial traction in the U.S. market following FDA clearances. Baird Medical aims to expand in the U.S., offering minimally invasive microwave ablation technology as an alternative to traditional thyroidectomy for benign thyroid tumors. The company recently completed a business combination with ExcelFin Acquisition Corp. and began trading on Nasdaq under the ticker symbol BDMD on October 2, 2024.

Baird Medical Investment Holdings (NASDAQ: BDMD) has successfully listed on the Nasdaq exchange, marking its transition to a public company. The company, a leading microwave ablation (MWA) medical device developer in China, began trading under the ticker symbol 'BDMD' on October 2, 2024. This milestone follows Baird Medical's recent expansion into the U.S. market after receiving FDA 510(k) clearances.

Co-Founder Wenyuan Wu rang the Opening Bell to celebrate the occasion. The company's technology offers a minimally invasive alternative to thyroidectomy for patients with benign thyroid tumors, addressing a significant market need in the U.S., where 150,000 thyroidectomies are performed annually. Baird Medical's MWA technology aims to provide safer and more efficient procedures for thyroid care, benefiting both patients and physicians.

Baird Medical Investment Holdings (NASDAQ: BDMD), a leading microwave ablation (MWA) medical device developer and provider in China, has announced its participation in Roth's 3rd Annual Healthcare Opportunities Conference on October 9, 2024, in New York City. The company's management plans to host one-on-one and small group meetings with institutional investors at the event.

This participation comes as Baird Medical expands its footprint in the U.S. market following recent FDA clearance for its minimally invasive microwave ablation technology. The company's technology offers a promising alternative to thyroidectomy for patients with benign thyroid tumors. Currently, 150,000 thyroidectomies are performed annually in the United States.

Baird Medical's expansion into the U.S. market follows its receipt of US FDA 510(k) clearances, positioning the company to tap into a significant market opportunity in thyroid tumor treatment.